Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Swisher · SciRah

Researcher profile · Semantic Scholar

E. Swisher

Share profile

E. Swisher — researcher profile on SciRah

h-index: 73
Works: 381
Citations: 31K

Most-cited papers

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R. Miller, A. Leary, C. Scott, V. Serra +12 more
2020Annals of Oncology430 citations Open access
Semantic Scholar
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A. Färkkilä, D. Gulhan, J. Casado, C. Jacobson +23 more
2020Nature Communications256 citations Open access
Semantic Scholar
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
Erika J. Lampert, A. Zimmer, M. Padget, A. Cimino-Mathews +14 more
2020Clinical Cancer Research180 citations Open access
Semantic Scholar
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
E. Swisher, T. Kwan, A. Oza, A. Tinker +30 more
2021Nature Communications179 citations Open access
Semantic Scholar
An expanded universe of cancer targets
W. Hahn, J. Bader, Theodore P. Braun, A. Califano +121 more
2021Cell178 citations Open access
Semantic Scholar
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
M. Bruand, D. Barras, M. Mina, E. Ghisoni +31 more
2021Cell Reports123 citations Open access
Semantic Scholar
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
J. Ledermann, A. Oza, D. Lorusso, C. Aghajanian +20 more
2020The Lancet Oncology110 citations Open access
Semantic Scholar
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F. Liu, M. Brady, U. Matulonis, Austin Miller +17 more
2022Journal of Clinical Oncology79 citations Open access
Semantic Scholar
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis
Miranda P. Steenbeek, M. V. van Bommel, J. Bulten, Julia A Hulsmann +18 more
2022Journal of Clinical Oncology71 citations Open access
Semantic Scholar
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
B. You, C. Purdy, L. Copeland, E. Swisher +16 more
2022Journal of Clinical Oncology68 citations Open access
Semantic Scholar
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and/or BRCA mutation-associated breast cancer (S1416): a randomised, phase 2 trial
E. Rodler, Priyanka Sharma, W. Barlow, J. Gralow +17 more
2023The Lancet Oncology67 citations Open access
Semantic Scholar
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
T. Kwan, A. Oza, A. Tinker, I. Ray-Coquard +17 more
2021JAMA Oncology61 citations Open access
Semantic Scholar
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
F. Batalini, N. Xiong, N. Tayob, M. Polak +11 more
2022Clinical Cancer Research54 citations Open access
Semantic Scholar
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
F. Menghi, Kalyan Banda, Pooja Kumar, R. Straub +10 more
2022Science Translational Medicine49 citations Open access
Semantic Scholar
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol
Miranda P. Steenbeek, M. V. van Bommel, J. Inthout, C. Peterson +8 more
2023International Journal of Gynecological Cancer48 citations Open access
Semantic Scholar
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
D. O'Malley, A. Oza, D. Lorusso, C. Aghajanian +18 more
2022Gynecologic Oncology45 citations Open access
Semantic Scholar
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study
B. You, Vasudha Sehgal, B. Hosmane, Xin Huang +11 more
2022Journal of Clinical Oncology39 citations Open access
Semantic Scholar
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Clifford M. Csizmar, Antoine N. Saliba, E. Swisher, S. Kaufmann
2021Cancers39 citations Open access
Semantic Scholar
Comparative genomics of high grade neuroendocrine carcinoma of the cervix
R. Hillman, R. Cardnell, J. Fujimoto, Won-Chul Lee +7 more
2020PLoS ONE39 citations Open access
Semantic Scholar
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
E. Swisher, C. Aghajanian, D. O'Malley, G. Fleming +15 more
2021Gynecologic Oncology37 citations Open access
Semantic Scholar
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W. Kim, R. McKay, M. Radke, Shi-Lin Zhao +20 more
2022Journal of Clinical Oncology35 citations Open access
Semantic Scholar
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
H. Gray, P. Chatterjee, Rachele Rosati, Lauren R Appleyard +15 more
2023npj Precision Oncology33 citations Open access
Semantic Scholar
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
E. Swisher, R. Kristeleit, A. Oza, A. Tinker +18 more
2021Gynecologic Oncology33 citations Open access
Semantic Scholar
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
G. Lui, R. Shaw, F. Schaub, Isabella N. Stork +12 more
2020EBioMedicine33 citations Open access
Semantic Scholar
Homologous recombination–deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants
Rohit Prakash, Yashpal Rawal, Meghan R. Sullivan, McKenzie K. Grundy +16 more
2022Proceedings of the National Academy of Sciences of the United States of America30 citations Open access
Semantic Scholar
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E. Chiorean, K. Guthrie, P. Philip, E. Swisher +12 more
2021Clinical Cancer Research28 citations Open access
Semantic Scholar
Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials.
S. Jorge, S. Masshoor, H. Gray, E. Swisher +1 more
2023The Journal of the National Comprehensive Cancer Network27 citations Open access
Semantic Scholar
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer
Nitasha Gupta, Tzu-Ting Huang, J. Nair, Daniel An +13 more
2022Science Translational Medicine26 citations Open access
Semantic Scholar
Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma
S. Shigeta, G. Lui, R. Shaw, Russell D. Moser +8 more
2021Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Shannon K. Rush, E. Swisher, R. Garcia, K. Pennington +3 more
2020Gynecologic Oncology25 citations
Semantic Scholar
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
O. Colomban, E. Swisher, R. Kristeleit, I. McNeish +6 more
2023EBioMedicine20 citations Open access
Semantic Scholar
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
K. Nešić, J. Krais, C. Vandenberg, Yi-Fan Wang +30 more
2023medRxiv20 citations Open access
Semantic Scholar
Progesterone Receptors Promote Quiescence & Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.
Laura J. Mauro, M. Seibel, Caroline H. Diep, A. Spartz +9 more
2021Journal of Clinical Endocrinology and Metabolism20 citations Open access
Semantic Scholar
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
N. Colombo, A. Oza, D. Lorusso, C. Aghajanian +22 more
2020Gynecologic Oncology15 citations Open access
Semantic Scholar
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial
C. Aghajanian, E. Swisher, A. Okamoto, K. Steffensen +12 more
2021Gynecologic Oncology13 citations Open access
Semantic Scholar
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase 3 trial ARIEL3
A. Clamp, D. Lorusso, A. Oza, C. Aghajanian +19 more
2021International Journal of Gynecological Cancer13 citations Open access
Semantic Scholar
An Alternate Diagnostic Algorithm for the Diagnosis of Intra-Epithelial Fallopian Tube Lesions
Marie E. Perrone, N. Reder, S. Agoff, R. Garcia +5 more
2020International Journal of Gynecological Pathology13 citations Open access
Semantic Scholar
Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care
D. Bowen, Catharine Wang, Allison M. Cole, B. Norquist +7 more
2020Contemporary Clinical Trials12 citations Open access
Semantic Scholar
Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer
T. Ghezelayagh, Brendan F. Kohrn, J. Fredrickson, Enna Manhardt +14 more
2022Cancer Research Communications11 citations Open access
Semantic Scholar
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
G. Konecny, A. Oza, A. Tinker, A. Oaknin +22 more
2021Gynecologic Oncology11 citations Open access
Semantic Scholar
Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation
Meghan R. Sullivan, Rohit Prakash, Yashpal Rawal, Weibin Wang +6 more
2021Cold Spring Harbor molecular case studies9 citations Open access
Semantic Scholar
A Phase 1 and Pharmacodynamic Study of Chronically-Dosed, Single-Agent Veliparib (ABT-888) in Patients with BRCA1- or BRCA2-Mutated Cancer; Platinum-Refractory Ovarian or Triple-Negative Breast Cancer
J. Manzo, S. Puhalla, S. Pahuja, Fei Ding +30 more
2022Cancer Chemotherapy and Pharmacology8 citations Open access
Semantic Scholar
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Sahana Somasegar, A. Weiss, B. Norquist, N. Khasnavis +8 more
2021Gynecologic Oncology8 citations
Semantic Scholar
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
C. Aghajanian, M. Bookman, G. Fleming, E. Swisher +7 more
2021Gynecologic Oncology8 citations Open access
Semantic Scholar
Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention
T. Ghezelayagh, L. Stewart, B. Norquist, Deborah J. Bowen +4 more
2020Familial Cancer8 citations
Semantic Scholar
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
Joseph W. Kim, Navid Hafez, H. Soliman, S. Fu +13 more
20208 citations
Semantic Scholar
#GeneticTesting: Using Social Media to Facilitate Communication about testing to Women (Preprint)
Tara Coffin, Deborah J. Bowen, Karen Lu, E. Swisher +16 more
2021JMIR Formative Research7 citations Open access
Semantic Scholar
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A. Färkkilä, D. Gulhan, J. Casado, C. Jacobson +23 more
2020Nature Communications7 citations Open access
Semantic Scholar
What’s in it for me? : A value assessment of gynecologic cancer clinical trials for Black women
A. Oluloro, S. Temkin, J. Jackson, E. Swisher +2 more
2023Gynecologic Oncology6 citations Open access
Semantic Scholar
Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
R. McKay, M. Radke, Y. Shyr, Shi-Lin Zhao +16 more
20216 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Radke×12
Invite
M. Radke — researcher profile on SciRah
R. Coleman×12
Invite
R. Coleman — researcher profile on SciRah
C. Aghajanian×11
Invite
C. Aghajanian — researcher profile on SciRah
A. Oza×9
Invite
A. Oza — researcher profile on SciRah

×9

Invite

D. O'Malley — researcher profile on SciRah

Invite

S. Goble — researcher profile on SciRah

Invite

B. Norquist — researcher profile on SciRah

Invite

A. Leary — researcher profile on SciRah

Invite

A. Oaknin — researcher profile on SciRah

Invite

S. Kaufmann — researcher profile on SciRah

Invite

L. Maloney — researcher profile on SciRah

Invite

K. Lin — researcher profile on SciRah